Objectives
More than one-third of Medicare beneficiaries are enrolled in a managed Medicare Advantage (MA) plan, yet there is little data comparing outcomes among MA Beneficiaries (MAB) compared to traditional Medicare Fee-for-Service Beneficiaries (FFSB). The objective of this study was to identify high-need, high-cost cohorts of MAB and FFSB and compare their healthcare resource utilization, costs, and quality outcomes.
Methods
This retrospective study used data from a national sample of MA encounter data and 100% Medicare Parts A, B, and D claims data from 2015-2017. A validated algorithm was applied to identify distinct clinical cohorts of high-need, high-cost beneficiaries in FFS and MA, including disabled under age 65, frail elderly, and major complex chronic patients. Propensity score matching was used to assure the populations had similar demographic and clinical characteristics; matching resulted in a study sample of 1,262,180 patients in both cohorts. We compared performance on a discrete set of health outcomes selected as relevant indicators of the impact of care management practices.
Results
Overall, MA performed better than FFS on 17 of 22 quality measures, including preventive care (e.g., 50% more likely to receive pneumonia vaccine; 18-27% more likely to be screened/treated for depression). MAB had 10% fewer inpatient stays, but higher use of outpatient and physician office visits. MAB were about 50% less likely to be hospitalized for potentially preventable complications. Total medical and pharmacy spend was 15% lower in MA.
Conclusions
This study found significant differences in health outcomes of high-cost high-need MAB compared to similar FFSB. Enrollment in MA continues to rapidly expand, projected to reach 47% of Medicare by 2029. This study indicates the incentives in MA to better coordinate care and provide flexible medical/non-medical benefits are associated with better care at lower cost, which is the goal of value-based purchasing.
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
